BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Maryland Psychiatric Society - ECPv6.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Maryland Psychiatric Society
X-ORIGINAL-URL:https://mdpsych.org
X-WR-CALDESC:Events for Maryland Psychiatric Society
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20191109T083000
DTEND;TZID=America/New_York:20191109T163000
DTSTAMP:20191024T161317Z
CREATED:20190404T151233Z
LAST-MODIFIED:20191024T161317Z
UID:3410-1573288200-1573317000@mdpsych.org
SUMMARY:Psychopharmacology Update 2019
DESCRIPTION:BUY MPS MEMBER TICKETS HERE\nBUY NON MEMBER TICKETS HERE\n\nAbout The Program:\nPlease join us for the Maryland Psychiatric Society’s Annual Psychopharmacology Update in Baltimore! All of our dynamic sessions will be presented by a slate of distinguished faculty on a wide variety of topics tailored towards psychiatrists and mental health clinicians who need the most up-to-date information available. The course is meant for all clinicians who prescribe psychotropic medications\, and will address indications\, contraindications\, management of adverse events and more. It includes a focus on complex and challenging conditions\, atypical presentations and special populations throughout the life cycle. \nAgenda:\n9:00-10:00       Esketamine for Treatment Resistant Depression: How Special is Special K:Evolution\, Revolution or Fashion?– Adam Kaplin\, MD\, PhD \n10:00-11:00    Brexanolone: Clinical Considerations and Future Research Directions – Lindsay Standeven\, MD \n11:00-11:15     BREAK \n11:15-12:15     The Past and Future of Vagus Nerve Stimulation for Treatment Resistant Depression Scott Aaronson\, MD \n12:15-1:15       LUNCH \n1:15-2:15         Psilocybin Treatment of Depression and Tobacco Addiction- Matt Johnson\, Ph.D. \n2:15-3:15         Optimizing Psychiatric Treatment Regimens to Treat Pain – Liz Prince\, DO \n3:15-3:30         BREAK \n3:30-4:30         Deep TMS for OCD – Geoff Grammer\, MD \n  \nAbout The Speakers:\nScott Aaronson\, MD – is the director of clinical research at Sheppard Pratt. He has particularly been involved with the development of new strategies to alleviate the symptoms in treatment resistant mood disorders\, and has published numerous articles  on pivotal studies in the use of devices—Transcranial Magnetic Stimulation (TMS) and Vagus Nerve Stimulation (VNS) in the treatment of severe refractory mood disorders. \nGeoff Grammer\, MD – is an Assistant Professor of Psychiatry at the Uniformed Services University. He serves as Greenbrook TMS NeuroHealth’s Chief Medical Officer\, the largest TMS provider in the United States with over 80 centers.  Dr. Grammer created one of the very first TMS Therapy centers in the United States and is valued as a leading practitioner of TMS Therapy by his colleagues. \nMatt Johnson\, Ph.D. – is an Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins Hospital. His research interests include human behavior change\, especially in the context of addiction recovery. His expertise is in addiction medicine\, drug abuse research and drug dependence \nAdam Kaplin\, MD\, PhD – is an Assistant Professor of Neurology & Psychiatry and Behavioral Sciences at Johns Hopkins Hospital. He is the Chief Psychiatric Consultant for the Johns Hopkins MS Center and his areas of expertise include Neuropsychiatry\, Mental Health Information Technology and Psychoneuroimmunology. \nLiz Prince\, DO – is an Instructor of Psychiatry at Johns Hopkins University. Following medical school at the Touro College of Osteopathic Medicine in New York City\, Dr. Prince completed her internship and residency in psychiatry at Johns Hopkins. She went on to a fellowship in consultation-liaison psychiatry at University of Maryland Medical Center before returning to join the faculty at Johns Hopkins. \nLindsay Standeven\, MD – is in her last year of fellowship training in Reproductive Psychiatry in the Department of Psychiatry and Behavioral Science at Johns Hopkins. She is certified by the American Board of Psychiatry And Neurology and completed her residency at Johns Hopkins University School of Medicine. \n  \nGoals/Objectives:\nAt the end of this educational activity\, the learner will be able to: \n\nDescribe the features of a treatment resistant depression (TRD)\nIdentify potential candidates most likely to benefit from vagus nerve stimulation (VNS) for depression\nDifferentiate between scales rating severity of depression from scales evaluating quality of life and how each should impact on clinical decision making.\nDescribe differences in magnetic field generations with different TMS coil types\nName areas of the brain implicated in OCD and affected by deep TMS\nDefine outcomes in the deep TMS for OCD clinical trial that was considered in FDA approval\nIdentify disorders which are being investigator regarding treatment with psilocybin\nIdentify risks of administering psilocybin\nDescribe safety mechanisms for mitigating risks in psilocybin research\nLearn the risks\, benefits and alternatives to the use of esketamine for treatment resistant depression.\nUnderstand the presumed basic mechanism of action of low dose esketamine and why that results in unique clinical characteristics of this novel\, recently approved antidepressant therapy\nDescribe to patients the basis for the approval by the FDA of this treatment\, and what the risks are and side effects\, as well as unique clinical applications\nIdentify the somatic and psychiatric relative contraindications to the use of esketamine\nDiscuss the epidemiology of perinatal depression and anxiety\nUnderstand of biological background that fueled interest in Brexanalone\nReview scientific literature on Brexanalone and strength of findings\nList clinical challenges in Brexanalone administration\nUnderstand how pain and psychiatric illness are related\nDiscuss how pain medications relate to psychiatric illness\nIdentify psychiatric treatments that can impact pain\nReview management strategies for patients with psychiatric illness and pain disorders\n\nAccreditation/Designation Information\nThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of American Psychiatric Association (APA) and Maryland Psychiatric Society (MPS).   The APA is accredited by the ACCME to provide continuing medical education for physicians.  The APA designates this live activity for a maximum of 6 AMA PRA Category 1 Credit(s) TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nThis activity is approved for a maximum of 6 hours of Category I Continuing Education for Social Workers by the Maryland Board of Social Workers. \nThis activity is approved for a maximum of 6 hours of Continuing Education for Psychologists by the Maryland Board of Examiners for Psychologists. \n  \n  \n  \n  \n  \n  \n  \n  \n  \n 
URL:https://mdpsych.org/meetings/psychopharmacology-update-2019/
LOCATION:Conference Center at Sheppard Pratt\, 6501 North Charles Street\, Towson\, MD\, 21204\, United States
ORGANIZER;CN="Maryland Psychiatric Society":MAILTO:mps@mdpsych.org
END:VEVENT
END:VCALENDAR